Redemption of Medical Drugs in Clinical Trials

To Medical Drug and Device Makers, and Clinical Trial Managers

Reference: Redemption of Medical Drugs in Clinical Trials

Dear Sir or Madam,

Following up the report on the clinical trial posted on the FDA’s website clinicaltrials.gov, we would like to invite you to give us the opportunity to test your drug one more time to detect any possible endotoxin or non-endotoxin pyrogens, using our advanced Monocyte Activation Test (MAT) system.

We believe that many clinical trials have failed not because of the drugs’ inefficacy, but because of pyrogenic contaminants that were not detected by the current compendial methods.

We also believe that some of the losses associated with clinical trial failures can be redeemed by accurately quantifying the total pyrogen levels (endotoxins and non-endotoxin pyrogens) which may have caused adverse effects during trials.

Using our advanced Monocyte Activation Test system to detect endotoxins and particularly non-endotoxin pyrogens that cannot be detected by the horseshoe crab test (LAL), we will provide a comprehensive safety status report on your therapeutic products, which will enable you to decide whether to revisit your product before writing it off.

Our capability statement and order form are posted for your consideration. We look forward to hearing from you.

Best regards, 

Djikolngar Maouyo, Ph.D.

President